NAGE · Niagen Bioscience, Inc.
$3.19
-0.21 (-6.18%)
At close · Jul 23
Market Cap
$254.07M
Shares
79.64M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-29 | 2026-06-24 | |
| 8-K | 2026-05-06 | — | |
| 10-Q | 2026-05-06 | 2026-03-31 | |
| DEF 14A | 2026-04-29 | 2026-06-24 | |
| 8-K | 2026-03-19 | — | |
| 8-K | 2026-03-04 | — | |
| 10-K | 2026-03-04 | 2025-12-31 | |
| 8-K | 2026-02-26 | 2026-02-24 | |
| 8-K | 2025-12-22 | 2025-12-18 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-11-04 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-10-06 | — | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-08-06 | — | |
| 8-K | 2025-07-29 | 2025-07-25 | |
| 8-K | 2025-06-27 | 2025-06-24 | |
| 10-Q | 2025-05-07 | 2025-03-31 | |
| 8-K | 2025-05-07 | — | |
| DEF 14A | 2025-04-29 | 2024-12-31 | |
| 8-K | 2025-03-19 | 2025-03-17 | |
| 8-K | 2025-03-04 | — | |
| 10-K | 2025-03-04 | 2024-12-31 | |
| 8-K | 2025-02-27 | 2025-02-25 | |
| 8-K | 2024-12-16 | 2024-12-13 | |
| 8-K | 2024-12-04 | — | |
| 8-K | 2024-11-21 | 2024-11-20 | |
| 8-K | 2024-10-31 | — | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-10-11 | 2024-10-08 | |
| 8-K | 2024-09-20 | 2024-09-19 | |
| 8-K | 2024-08-07 | — | |
| 10-Q | 2024-08-07 | 2024-06-30 | |
| 8-K | 2024-07-16 | — | |
| 8-K | 2024-06-25 | 2024-06-19 | |
| 8-K | 2024-06-24 | 2024-06-20 | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-08 | — | |
| DEF 14A | 2024-04-25 | — | |
| 10-K | 2024-03-06 | 2023-12-31 | |
| 8-K | 2024-03-06 | — | |
| 8-K | 2023-12-13 | 2023-12-08 | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-11-08 | — | |
| 8-K | 2023-08-09 | — | |
| 10-Q | 2023-08-09 | 2023-06-30 | |
| 8-K | 2023-06-20 | 2023-06-15 | |
| 10-Q | 2023-05-10 | 2023-03-31 | |
| 8-K | 2023-05-10 | — | |
| DEF 14A | 2023-04-28 | 0001-01-01 |
Showing 1–50 of 109 filings
Key facts
CIK
1386570
CUSIP
171077407
13F (30d)
18 filings
18 filers
Visit website
Investor relations